BioNTech Shares Plunge as Pfizer Exits Stake
Published on 11/15/2025 at 03:07 | Redaktion boerse-global.de
A seismic development has rocked BioNTech’s stock valuation following the complete divestment of Pfizer’s substantial shareholding. The long-standing pandemic partner executed an accelerated block trade, offloading its entire remaining position of 4.55 million shares overnight, sending the biotechnology firm’s equity into a tailspin. This dramatic separation raises critical questions about the strategic implications for the Mainz-based company’s future trajectory.
Amid the market turmoil triggered by Pfizer’s exit, BioNTech had previously released third-quarter 2025 financial results that presented a mixed performance picture. Revenue figures provided a positive surprise, with the company generating €1.52 billion, substantially exceeding market expectations. This outperformance was primarily driven by a significant payment received through Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
